Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRX-0706 in advanced solid tumors
NCT06036121Phase 1Active, not recruiting
- Sponsor
- Adcentrx Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ADRX-0706 in solid tumor, urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and 5 more (2 arms), sponsored by Adcentrx Therapeutics. Primary endpoint: Incidence of adverse events. Started Sep 2023; status: active, not recruiting.
02
Drugs
ADRX-0706
03
Conditions
solid tumorurothelial carcinoma (UC)triple-negative breast cancer (TNBC)Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06036121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036121.